This study is for newly diagnosed WHO Grade IV malignant glioma patients to determine whether
an investigational drug known as marizomib (MRZ) will improve the treatment of newly
diagnosed glioblastoma patients by delaying the growth of the cancer, reducing the size of
the tumor, and/or improving survival. Marizomib (MRZ) is being added to standard-of-care
treatments of radiotherapy (RT), temozolomide (TMZ), and Optune.